In the future, adjunct therapy involving NOD-2L, TLR-4L and TB drugs may have enough potential to reduce the dose and duration of treatment of TB patients.
Introduction
Despite the availability of highly effective drug regimens, tuberculosis (TB) continues to wreck public health worldwide. Furthermore, the threat is compounded by the emergence of the AIDS pandemic and drug-resistant strains of Mycobacterium tuberculosis (Mtb) [1] . The bacillus Calmette-Guérin (BCG) vaccine is available against TB, but its role is highly controversial due to its variable efficacy globally [2] . Hence, there is an urgent need to develop innovative strategies to treat TB. Since recently, novel therapies employing immunomodulators are being explored for treating various ailments such as cancer, autoimmunity and cardiac diseases [3] [4] [5] [6] . Immunotherapy holds great promise for various diseases, but no serious effort has been undertaken in the case of TB.
Adaptive immunity plays a vital role against Mtb due to its specificity and memory response. However, in the last few decades, the focus has been generated more on innate immunity. Innate cells perform multiple functions employing various pattern recognition receptors such as Toll-like receptors (TLRs), C-type lectin receptors and Nod-like receptors (NLRs) [7, 8] . Recently, the experimental model of TB has highlighted the importance of TLRs in protecting against Mtb [9] . TLRs contribute substantially in resistance against Mtb, but this attribute is not endowed to their function alone. Furthermore, the recognition of antigens by NOD-2 (nucleotide-binding oligomerization domain 2), a member of the NLR family also critically contributes in imparting immunity against bacteria or viruses [10] [11] [12] . This indicates that synergistic triggering through TLRs and NOD-2 may result in a stronger and enduring immune response that could restrict the growth of Mtb. The WHO has also recommended the use of immunomodulators as an adjunct therapy to the existing TB drugs [13] .
Dendritic cells (DCs) are the most potent antigen presenting cells that activate naive T cells. Despite their key role in initiating cell-mediated immunity, DCs exhibit several deficiencies including inferior bactericidal activity and limited migration to the draining lymph nodes (DLNs) [14] . Noteworthy, DCs are the major players in bridging innate and adaptive immunity. Targeting DCs in order to improve their bactericidal activity could strengthen both innate and adaptive immunity. Taking into consideration the above-mentioned facts, we designed an innovative approach to bolster DC efficacy by delivering signals via NOD-2 and TLR-4 (N 2 T 4 ). It is important to mention that NOD-2 is expressed in the cytoplasm. To ligate with receptors, a ligand for NOD-2 is internalized into acidified vesicles by endocytosis dependent on the clathrin and dyamin pathways [15] . We selected N-glycolyl muramyl dipeptide (MDP) as a NOD-2 agonist as it exhibits 10 to 100 fold more potent immunogenicity than the commonly studied N-acetylated MDP [16] . We used LPS as a source of TLR-4 ligand (TLR-4L). Recently, the FDA has approved the use of LPS in medicines, which has opened new avenues to harness its remedial potential [17, 18] . DCs activated by signaling through NOD-2 and TLR-4 (N 2 T 4 .DCs) exhibited improvement in bactericidal activity. Further, N 2 T 4 triggering afforded a favorable window for TB drugs to achieve an optimum immune response against Mtb. Importantly, N 2 T 4 .DCs required a considerably lesser dose of the drug to kill the Mtb. Activated DCs also induced a better T cell response in vivo due to improved migration and augmented autophagy. This study may open new avenues of adjunct therapy employing drugs in combination with signaling through NOD-2 and TLR-4 in successfully treating TB.
Material and Methods
Animals C57BL/6 mice, 6-8 weeks of age, were procured from the institute's animal facility. All experiments were approved by the Institutional Animal Ethics Committee (No. 55/1999/CPCSEA), Ministry of Environment and Forests, Government of India.
Antibodies and Reagents
All standard chemicals and reagents used in the study were purchased from Sigma (St. Louis, Mo., USA), and antibodies and recombinant cytokines from BD Biosciences (San Diego, Calif., USA) unless stated otherwise. TLR-4L, i.e. LPS, and NOD-2 ligand (NOD-2L), i.e. N-glycolyl MDP, were procured from Invitrogen (San Diego, Calif., USA). Anti-mouse LC-3 and inducible nitric oxide synthase (iNOS) antibodies were obtained from Sigma and Abcam (Cambridge, UK), respectively.
Mycobacterial Strain and Antigens
Mtb strains (H37Rv and H37Ra) were provided by Dr. V.M. Katoch, National JALMA Institute for Leprosy and Other Mycobacterial Diseases, India, and Salmonella typhimurium was provided by Dr. Amitabha Mukhopadhyay, National Institute of Immunology, India. Mtb was cultured in Middlebrook 7H9 broth containing glycerol (0.2%) and Tween-80 (0.05%) supplemented with albumin, dextrose and catalase. The viability of the bacteria was determined by plating on Middlebrook 7H11 medium supplemented with oleic acid, albumin, dextrose and catalase, and then counting the number of colony-forming units (CFU). S. typhimurium was cultured in LB broth. Viability was determined by plating on LB agar medium.
Culture of Bone Marrow-Derived DCs and Their Stimulation via NOD-2 and TLR-4
Bone marrow-derived DCs were cultured according to Lutz et al. [19] . Briefly, bone marrow cells (BMCs) were flushed aseptically from femurs and tibias. For DC cultures, cells were grown in RPMI 1640 (Invitrogen, Life Technologies, Eugene, Oreg., USA) containing FCS (10%; Gibco, Grand Island, N.Y., USA) supplemented with penicillin (100 U/ml), streptomycin (100 mg/ml), Lglutamine (100 m M ), granulocyte-macrophage colony-stimulating factor (GM-CSF) (2 ng/ml) and murine r-IL-4 (4 ng/ml) for 6 days. Cultures were maintained in a humidified atmosphere and 5% CO 2 at 37 ° C. The medium was replenished on day 3. DCs were then harvested, washed and stimulated with N-glycolyl MDP (10 μg/ml) and LPS (5 ng/ml), respectively, for 24 h.
For macrophages, BMCs were grown in RPMI 1640 + FCS and replenished with L929 (20%) supernatant, as a source of M-CSF. Later, macrophages were harvested, washed and stimulated with NOD-2L (10 μg/ml) and TLR-4L (10 ng/ml) for 24 h.
In vitro Infection with Bacteria and CFU Assay
Bacterial aliquots were rapidly thawed, washed 2× with PBS and resuspended in RPMI 1640 + FCS. To remove clumps, bacteria were passed through an insulin syringe. DCs were infected with the indicated multiplicity of infection (MOI). Cells were infected with Mtb for 4 h (MOI 1: 5) and with Mycobacterium smegmatis for 3 h (MOI 1: 5) . After infection, cells were washed extensively to remove extracellular bacteria, and were then further incubated with NOD-2L and TLR-4L for 24 and 72 h with the mycobacteria in the presence of amikacin (2 μg/ml). After 24 or 72 h, cell supernatants were removed, saponin (0.1%) was added to lyse the cells and plating was done with 10× serial dilution on a 7H11 agar plate. The colonies were enumerated at 3 days and 3 weeks for M. smegmatis and Mtb, respectively, after the incubation at 37 ° C in a humidified CO 2 (5%) atmosphere. Where indicated, isoniazid (INH; 25 μg/ml), rifampicin (RIF; 0.5 μg/ml) or the iNOS inhibitor Nmonomethyl-L -arginine (1 m M ) was added, along with NOD-2L and TLR-4L, for 24 h. For S. typhimurium experiments, DCs were infected with the bacterium (MOI 1: 10) for 30 min. After infection, cells were extensively washed and incubated for 1 h in cell culture medium containing gentamicin (50 μg/ml). The cells were washed and cultures were maintained in medium containing gentamicin (10 μg/ml) for 16 h in the presence or absence of NOD-2L and TLR-4L. For enumeration of the bacteria, cells were lysed with Triton X-100 (0.1%) and serial dilution lysates were plated onto LB agar plates. To block autophagy, DCs were treated with the autophagy inhibitor wortmannin (for 2 h) prior to Mtb infection, but chloroquine (10 μ M ) was present throughout the culture (24 h).
Nitric Oxide Production/Release
Supernatants were harvested after 4 h of infection followed by stimulation via either NOD-2 or TLR-4 or N 2 T 4 for 48 h. The nitric oxide (NO) level was measured by the Griess method. Briefly, supernatants (50 μl) were incubated with an equal volume of Griess reagent for 5 min at room temperature. Later, absorbance was measured at 595 nm.
Cytokine Assessment by ELISA
The cytokines IL-6 and IL-12 were detected in culture supernatants at an indicated time point by standard ELISA, according to manufacturer's instructions.
DC and T Cell
Coculture N 2 T 4 .DCs (C57BL/6) were cocultured with magnetic-associated cell sorted (98%) purified CD4 T cells (BALB/c) at a ratio of 1: 5. After 72 h, 3 H-thymidine (0.5 μCi/well) was added to the cultures. The plates were harvested after 16 h and the radioactivity incorporated into the cells was measured as counts/min (cpm) by scintillation counting. In parallel, cultures were set for 48 h for cytokine assessment (IFN-γ) by ELISA and intracellular staining. For intracellular staining, cells were treated with PMA and ionomycin for 3 h followed by brefeldin for 2 h and then stained for IFN-γ.
RT-qPCR for the Quantification of IFN-γ and iNOS
Total RNA was isolated by Trizol reagent from Mtb-infected DCs stimulated via NOD-2, TLR-4 or N 2 T 4 for 6 h or from the lungs of Mtb-challenged mice, and followed by immunotherapy, according to the manufacturer's instruction (Invitrogen, Carlsbad, Calif., USA). RNA was quantified with the help of a NanoDrop spectrophotometer. A260/A280 ratio of all samples was in the range of 1.90-2.00. Intactness of RNA samples was determined with the help of formaldehyde denaturing agarose gel-electrophoresis. DNA contamination from RNA samples was removed by amplification grade DNase. Briefly, RNA samples (1 μg) were incubated with DNase (1 U) for 15 min in the reaction buffer. After the incubation, DNase activity was terminated by stop solution. 
Propidium Iodide and Annexin V Assays
DCs were stimulated through NOD-2, TLR-4 or N 2 T 4 at 37 ° C and 5% CO 2 for 24 h. This was followed by resuspension of the cells in binding buffer (0.01 M HEPES, pH 7.4, 0.14 M NaCl and 2.5 m M CaCl 2 ). FITC-conjugated annexin V (5 μl/tube) and 5 μl of propidium iodide (50 μg/ml) were added to the cells and incubated in the dark for 15 min at room temperature. Later, binding buffer (400 μl) was added and cells were acquired immediately, employing a BD FACS Calibur flow cytometer; analysis was done using BD DIVA software.
Western Blotting
Mtb-infected DCs were stimulated through NOD-2, TLR-4 or N 2 T 4 for 2 h. Later, cells were harvested, washed and lysed in lysis buffer (RIPA buffer, protease and phosphatase inhibitor cocktail). Proteins in the supernatants were estimated and an equal concentration was subjected to SDS-PAGE. After transfer to the nitrocellulose membrane and subsequent blocking, the membranes were immunoblotted with antibodies against LC3-I/LC3-II and actin as a loading control. Blots were developed using a chemiluminescence kit (Amersham Pharmacia Biotech, Amersham, UK). Blots were scanned with the help of a phosphoimager (Fujifilm, Tokyo, Japan) and image analysis was performed with MultiGauge software. For iNOS, Mtb-infected DCs were stimulated through NOD-2, TLR-4 or N 2 T 4 for 16 h and the expression was analyzed by Western blotting.
Flow Cytometric Analysis for the Expression of Activation Markers
Mtb-infected or uninfected DCs stimulated with NOD-2 and TLR-4 in the presence or absence of IL-12-neutralizing antibodies for 24 h were harvested and resuspended in staining buffer (2% FCS, 2 m M NaN 3 in PBS). To block nonspecificity, cells were first incubated with Fc block (anti-CD16/32 Ab) for 25 min at 4 ° C. The cells were washed and then stained with fluorochrome-conjugated antibodies specific for CCR7, and the control cells with isotypematched antibodies for 30 min at 4 ° C. Cells were washed and fixed with paraformaldehyde (1×). Data were collected using FACS ARIA II and analyzed with BD DIVA software.
siRNA Knockdown of NOD-2 DCs were incubated with NOD-2 siRNA (1 μ M ) in Accell siRNA delivery media, as per the manufacturer instructions (Thermo-Scientific Dharmacon). After 48 h, inhibition in the expression of NOD-2 was detected at mRNA level by RT-qPCR.
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For functional assays, DCs incubated with NOD-2 siRNA for 72 h were washed and restimulated with N 2 T 4 L in RPMI + FCS for 24 h. Later, IL-6 production was detected in supernatants by ELISA.
Migration of DCs in vivo
DCs were infected with Mtb followed by stimulation through N 2 T 4 for 24 h. Later, N 2 T 4 .DCs (3 × 10 6 cells) were labeled with CFSE (5 μ M ) and adoptively transferred into mice. After 72 h, the mice were sacrificed, the DLNs were isolated and a single-cell suspension was prepared. The frequency of CFSE-positive cells was quantified employing flow cytometry.
Therapeutic Strategy
Mice were aerosol-challenged with Mtb, and 100 CFU were deposited in the lungs. Later, the animals were injected twice subcutaneously with a gap of 15 days with N 2 T 4 L and the controls with NOD-2L or TLR-4L. The dose of NOD-2L versus TLR-4L for an in vivo assay was selected on the basis of the reduction in CFU in the lungs of Mtb-challenged animals treated with different doses of NOD-2L (3, 30 and 300 μg/100 μl PBS) or TLR-4L (0.1, 1 and 10 μg/100 μl PBS) alone or in combination, twice with a gap of 15 days. After the last injection, the animals were sacrificed and CFU were determined in the lungs. Total CFU per gram of lung were calculated. The optimum reduction in CFU was noticed with 3 μg/ 100 μl of NOD-2L and 0.1 μg/100 μl of μl TLR-4L, so these doses were selected to perform all in vivo experiments.
Isolation of Lymphocytes
Mice were aerosol-challenged with Mtb followed by treatment with NOD-2L, TLR-4L or N 2 T 4 L. After 45 days of aerosol challenge with Mtb, the mice were sacrificed . The lungs were perfused and the spleen and lymph nodes (mediastinal) were harvested and a single-cell suspension was prepared. Briefly, lymphocytes from the spleen were prepared by lysis of red blood cells with ACK lysing buffer (0.15 M NH 4 Cl, 10 m M KHCO 3 and 88 m M EDTA), washed 3× with PBS and resuspended in RPMI 1640 + FCS. Viability of the cells was assessed by the trypan blue dye exclusion method.
Staining of the T Cell Surface Markers and Intracellular IFN-γ Expression
Cells were incubated with Fc block for 25 min and stained for the expression of CD4, CD8, CD69, CD44 and CD62L by their respective antibodies. Cells were fixed in 1% paraformaldehyde. For intracellular expression, cells stained for the surface CD4 and CD8 molecules were fixed with 4× paraformaldeyde for 30 min followed by permeabilization with 0.01% saponin in PBS for 30 min at 4 ° C. Later, cells were incubated with anti-IFN-γ antibody in a staining buffer containing 0.01% saponin. The usual steps of washing were performed after each incubation. The control cells were stained with the respective isotype-matched antibodies. Cells were acquired in FACSAria II and analyzed with DIVA software.
T Cell Proliferation
Lymphocytes (2.5 × 10 5 cells/well) were cultured in round-bottom, 96-well plates, in 200 μl of RPMI 1640 + FCS 10% and purified protein derivative (PPD; 6 μg/ml) for 48 h. Cells cultured with the medium alone (without antigen) were used as a control. Later, cultures were pulsed with 0.5 μCi of 3 H-thymidine (Amersham Pharmacia Biotech). The plates were harvested after 16 h onto glassfiber filter mats using a Tomtec Harvester96 (Tomtec, Hamden, Conn., USA). Radioactivity incorporated into the cells was measured by liquid scintillation spectroscopy utilizing Wallac 1450 MicroBeta TriLux (Perkin Elmer, Waltham, Mass., USA).
Histopathology
Mice were sacrificed and lung tissues were fixed in buffered formalin (10%). Histological sections were stained using hematoxylin and eosin. Photomicrographs were captured on an Olympus IX71 microscope and displayed at ×40 magnification.
Statistical Analysis
Data were analyzed by one-way analysis of variance (ANOVA) with the post-Tukey-Kramer multiple-comparison test by using GraphPad Prism software.
Results

Signaling through N 2 T 4 Enhances the Activation of DCs
This study focused on improving DC efficacy by exploring their potency through N 2 T 4 signaling. We observed that DCs triggered through TLR-4 showed substantial production of IL-6 (p < 0.001) and IL-12 (p < 0.001; fig. 1 a, b) . This effect was observed to be dose dependent. In contrast, triggering through NOD-2 failed to activate DCs, demonstrated by a lesser release of IL-6 and IL-12. However, it was quite interesting to note that signaling of NOD-2 in conjunction with TLR-4, i.e. N 2 T 4 , significantly enhanced the yield of both IL-6 (p < 0.01) and IL-12 (p < 0.01; fig. 1 a, b) . We observed the optimum release of IL-6 and IL-12 with 10 μg/ml of NOD-2L and 5 ng/ml of TLR-4L. In contrast, 80 ng/ml of TLR-4L on its own induced a significantly lower release of IL-6 (p < 0.01) and IL-12 (p < 0.01). Hence, in all subsequent experiments, a dose of 10 μg/ml NOD-2L and 5 ng/ml TLR-4L was selected. We also confirmed and validated the specificity of our results in DCs by knocking down the NOD-2 expression through siRNA (N 2KD ; online suppl. fig. S1 ; see www.karger.com/doi/10.1159/000439591 for all online suppl. material) and, with its inhibitor CLI-095, blocking TLR-4 signaling (T 4i ). Interestingly, compared to wild-type DCs, N 2 T 4 signaling showed no release by N 2KD T 4i .DCs ( fig. 1 c) .
N 2 T 4 -Elicited DCs Showed Enhancement of T Cell
Proliferation and IFN-γ Production N 2 T 4 .DCs acquired a significantly (p < 0.001) higher capacity to induce IFN-γ production by allogeneic CD4 T cells, as corroborated by the ELISA and flow cytometry results ( fig. 2 a, b) . Further, the improved performance of N 2 T 4 .DCs was further authenticated by the substantial (p < 0.0001) proliferation of T cells ( fig. 2 c) . These observations demonstrate that signaling of DCs through N 2 T 4 has a strong bearing on improving the activation of T cells.
Signaling of DCs through N 2 T 4 Restricted the Intracellular Growth of Bacteria
Based on the above results, we subsequently monitored the bactericidal efficacy of the N 2 T 4 .DCs. DCs infected with the H37Ra strain of Mtb on stimulation with N 2 T 4 for 24 h (p < 0.01) and 72 h (p < 0.05) significantly inhibited the intracellular growth of the bacterium ( fig. 3 a) . Further, this phenomenon was corroborated by demonstrating the effect on a virulent strain of Mtb (H37Rv; fig. 3 b) . Furthermore, it appeared that N 2 T 4 signaling of DCs could be a unique strategy to inhibit the growth of an array of intracellular pathogens, since it not only retarded the growth of fig. 3 a, b) but also M. smegmatis (p < 0.01) and S. typhimurium (p < 0.05; fig. 3 c; online suppl. fig. S5 ). It is important to mention here that the reduction in bacterial burden is not due to a differential uptake of Mtb by DCs. The bactericidal activity of DCs was demonstrated by first infecting DCs with bacteria for 4 h. Later, infected DCs were stimulated through N 2 T 4 . It was further confirmed by plating cell lysates of infected DCs at the initial time point (after 4 h) of infection, which showed no difference in the uptake of Mtb (online suppl. fig. S2 ).
N 2 T 4 Triggering of DCs Potentiated RIF and INH Mediated the Killing of Mtb
We also discerned that signaling of Mtb-infected DCs through N 2 T 4 considerably boosted the killing efficacy of the anti-TB drugs RIF (p < 0.01) and INH (p < 0.01), when compared with the drugs alone ( fig. 3 d, e) . Interestingly, N 2 T 4 L + RIF and N 2 T 4 L + INH showed a 75 and 60% reduction, respectively, in the bacterial burden when compared to RIF (37%) or INH (46%) alone. It may be concluded from these results that the adjunct therapy involving NOD-2L and TLR-4L in conjunction with INH and RIF may have an important implication in considerably improving the efficacy of anti-TB drugs to restrict the growth of Mtb. demonstrated by the conversion of LC3-I to LC3-II ( fig. 4 a) , which is a prominent indicator of autophagy [20] . This phenomenon was further confirmed by blocking autophagy, using its inhibitors wortmannin (p < 0.01) or chloroquine (p < 0.05), which significantly restored the survival of Mtb in N 2 T 4 .DCs ( fig. 4 b) . We also discerned augmentation in the production of NO by Mtb-infected N 2 T 4 .DCs compared to control NOD-2L-or TLR-4L-treated DCs or untreated DCs (uDCs; fig. 4 c) . NO is an established indicator of bactericidal activity [21] . Furthermore, this finding was proved by quantifying the expression of iNOS by Western blotting and RT-qPCR ( fig. 4 d, e) . It is important to mention here that NO release by N 2 T 4 .DCs inhibited the survival of Mtb. This information was confirmed by the CFU data. N 2 T 4 .DCs failed to restrict Mtb growth in the presence of the iNOS inhibitor N-monomethyl-L -arginine ( fig. 4 f) . It can be concluded that N 2 T 4 triggering enhances the bactericidal activity of DCs by augmenting autophagy and NO release.
Signaling through N 2 T 4 Enhances the Ability of DCs to Migrate
It is important that the activated DCs should capture antigens from the site of infection and migrate to the DLNs to activate naive T cells. Therefore, next, we studied the migratory capacity of N 2 T 4 .DCs. Mtb-infected DCs activated through N 2 T 4 were CFSE-labeled and adoptively transferred into mice. It was observed that the frequency of Mtb-infected CFSE-positive N 2 T 4 .DCs in the DLNs was significantly (p < 0.01) higher than unstimulated counterparts ( fig. 5 a) . Similar results were noted in the uninfected N 2 T 4 .DCs. fig. 5 b) . CCR7 is responsible for the migration of DCs [22, 23] . IL-12 is known to upregulate the expression of CCR7 [24] . We demonstrated earlier that N 2 T 4 .DCs release greater amount of IL-12 ( fig. 1 b) .
Importantly, we observed that neutralization of IL-12 by using anti-IL-12 antibody reduced the expression of CCR7 on N 2 T 4 .DCs ( fig. 5 b) . These data suggest that N 2 T 4 -driven production of IL-12 by DCs upregulates the CCR7 expression on N 2 T 4 .DCs. lo phenotype on CD4 and CD8 T cells ( fig. 6 a, b) , consequently supporting the generation of effector memory T cells. These animals also exhibited a better ex vivo percentage of IFN-γ + CD4 (p < 0.01) and CD8 (p < 0.05) T cells ( fig. 6 c) . Furthermore, the elevated yield of IFN-γ was confirmed by RT-qPCR in the lungs of N 2 T 4 L-treated mice ( fig. 6 d) . Similarly, in vitro stimulation of cells with PPD showed a considerable enhancement of IFN-γ (p < 0.001) production and displayed TNF-α + CD4 T cells and T cell proliferation (p < 0.001; fig. 6 e-g).
N 2 T 4 L-treated animals manifested better protective efficacy against Mtb, as evident in the significant decline (p < 0.001) of the Mtb burden in the lungs ( fig. 7 a) . Fur- fig. 7 b) . Excitingly, lungs resected from the mice administered with N 2 T 4 L revealed significant (p < 0.001) augmentation in Beclin and iNOS ( fig. 7 c, d ), also showing the involvement of autophagy and NO ( fig. 4 ) as a mechanism of the reduction of bacterial burden upon stimulation through NOD-2 and TLR-4. It is important to mention that the Mtb-challenged mice treated with N 2 T 4 L were kept for 120 days, in order to study the sur- 
Discussion
Despite the availability of highly effective drug regimens against TB, many patients fail to comply with the treatment [25] . The threat posed by TB is further compounded by the emergence of the AIDS pandemic and multidrug-resistant, extensively drug-resistant and totally drug-resistant Mtb [1] .
Innate immunity plays a pivotal role in imparting protection against pathogens [26, 27] . It may also reinvigorate host immunity suppressed by anti-TB drugs [28] [29] [30] . Thus, we designed a simple and elegant approach of strengthening host immunity by potentiating DC function by delivering signals through N 2 T 4 . We studied its role in vitalizing the potency of TB drugs to kill Mtb.
Delivering signals through N 2 T 4 led to the emergence of the following major findings: (1) the enhanced activation of DCs, (2) the augmented ability of DCs to help T cells, (3) enhanced autophagy, NO release and a decline in the survival of the bacteria, (4) improved migration tovival of the treated mice. We did not observe any mortality in this group. This shows that the dose of N 2 T 4 used in the experiments elicited a response that was not lethal for animals that could lead to their death. wards lymph nodes due to increased CCR7 expression, (5) increased in vivo effector T cell memory response and release of IFN-γ and TNF-α and (6) a reduction in the drug dose and an improvement of the in vitro and in vivo potency of the drugs in killing Mtb. DCs are a bridging component of innate and adaptive immunity [31] . Consequently, we thought that targeting DCs through N 2 T 4 might be an appropriate immunotherapeutic approach in evoking host immunity against Mtb.
N 2 T 4 -Drug Adjunct Therapy Significantly Boosts in vivo Drug Efficacy in Restraining the Growth of Mtb
We observed that N 2 T 4 .DCs showed robust production of the cytokines IL-6 and IL-12. Mice deficient in IL12p40 are highly susceptible to Mtb infection [24, 32] . N 2 T 4 .DCs also showed enhanced competence in activating T cells. Furthermore, migration of DCs to lymph nodes is a crucial step for initiating the activation of T cells. N 2 T 4 treatment showed substantial increase in the pool of Mtb-loaded DCs in the DLNs. Importantly, N 2 T 4 triggering had no adverse effect on the viability of DCs (online suppl. fig. S3 ). It is important to mention that N 2 T 4 triggering enhances the bactericidal activity of macrophages as well (online suppl. fig. S4 ).
T cells require cognate interaction with DCs for their activation, proliferation and differentiation. However, recently, the contribution of innate receptors has been reported in clonal expansion of the effector T cells, independent of the occupancy of T cell receptors by the MHCII peptide [33] . Importantly, Mtb-challenged mice treated with N 2 T 4 L showed substantial T cell proliferation, with an abundant release of IFN-γ and TNF-α [34, 35] . In addition, it augmented the effector T cell memory response. Furthermore, the growth of Mtb was meticulously restricted even after 45 days of infection. Autophagy has been reported as exhibiting a dual role in Mtb protection. It targets the antigen to lysosomes for degradation and delivers antimicrobial peptides to Mtbharboring compartments. Simultaneously, it prevents an excessive inflammatory reaction in the host [36, 37] . In addition, it enhances the antigen-presenting ability of DCs to T cells [38] . Importantly, N 2 T 4 .DCs showed an augmentation of autophagy and NO release and a signif- icant contribution to the reduction of the intracellular survival of Mtb. The expression of Beclin and iNOS in the lungs of Mtb-challenged mice treated with N 2 T 4 L also suggests autophagy and NO release to be a mechanism for conferring protection against Mtb.
The current TB regime is extremely efficient, but the major impediment is the long duration of 6 months, which inevitably gives rise to several side effects [39] . Still, the remarkable potency of TB drugs cannot be ignored. Henceforth, very pragmatically, we targeted N 2 T 4 to reinvigorate host immunity, and the outcome was some control of the survival of Mtb. Intriguingly, a significant increase in mycobacterial mortality was noted when Mtbinfected DCs were treated with RIF in conjunction with N 2 T 4 agonists. We further confirmed these results by administering INH in combination with N 2 T 4 L in Mtb-infected mice in vivo. Strikingly, animals inoculated with a 5-fold lesser dose (5 mg/kg BW) of INH bimonthly in conjunction with N 2 T 4 L showed a significant reduction in the bacterial load in the lungs, compared to the recommended daily dose of 25 mg/kg BW of INH only [40] . So this approach significantly reduced the dose of the drug. There is another fundamental benefit to INH-N 2 T 4 adjunct therapy, since the drug would kill the replicating Mtb and N 2 T 4 L would enhance host immunity for eliminating a nonreplicating, quiescent mycobacterium. So the INH-N 2 T 4 strategy may not only be advantageous in overcoming the side effects because of the lower drug dosage, it also alerts the host immunity to restrain the emergence of drug resistance in Mtb. Implementing this innovative drug + N 2 T 4 therapy may be a prudent approach in the future to effectively treat TB patients.
